Biohaven dropped 44% in premarket trading after the FDA declined to approve Vyglxia, citing issues with trial design even as data showed slower disease progression.The post Why Did Biohaven Stock Collapse in Premarket Today? FDA Rejects Its Lead Drug Vyglxia appeared first on Tokenist.